Lars Rebien Sørensen, who chairs the Novo Nordisk Foundation, will join its board as an observer while the company seeks a ...

NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.

Jørgensen will stay on as CEO temporarily for an undetermined period of time “to support a smooth transition” as the company looks for his replacement. Novo Nordisk’s value more than ...

In connection with the leadership transition, Lars Rebien Sørensen, Chair of the Novo Nordisk Foundation and former CEO of NVO, will initially join the company’s board as an observer ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

On May 19, BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following the announcement of a CEO transition. Analysts view the ...

As part of the transition period, Lars Rebien Sørensen ... with operating profit ranging from approximately $5.4 to $6.3 billion. 2 “Serving as Novo Nordisk’s CEO for the past eight years has been a ...

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated look at NVO stock prospects.

Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...